Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2021 | MDS: the direction the field is headed

Moshe Mittelman, MD, Tel Aviv Sourasky Medical Center, Tel Aviv University, Tel Aviv, Israel, shares his thoughts on where he believes the field of myelodysplastic syndromes (MDS) is headed in the future. Prof. Mittelman talks on 4 broad areas he believes will see the most development in the future: the genetic understanding of MDS and its incorporation into trials and clinical practice, the use of big data and machine learning in medical practice, the incorporation of quality of life and patient-reported outcome parameters, and the subsequent use of more non-invasive treatments, and the collaboration of government organizations, academic societies, patient advocacy groups as well as industry. In terms of the genetic understanding of MDS, Prof. Mittelman explains the prognostic value of genetic information and talks of the international effort into the mass collection of patient data and genetic information to better classify MDS. Machine learning and other digital techniques may enable enhanced diagnosis and may aid prognostic evaluation. This interview took place at the 16th International Congress on Myelodysplastic Syndromes, held virtually in 2021.